The New Paper

November 19, 2020

Pfizer announces final results from late-stage coronavirus vaccine trials

Pfizer and BioNTech announced that their coronavirus vaccine is 95% effective based on final results from late-stage clinical trials, improving from the 90% initially reported (based on interim results) last week. The companies plan to seek emergency use authorization from the FDA as early as this week and noted that they expect to produce 50M vaccines this year increasing to 1.3B in 2021).

Extra: The Pfizer and BioNTech vaccine uses mRNA, the same genetic tool as the Moderna vaccine (which showed 94.5% efficacy based on interim results announced on Monday).

This story is from the November 19, 2020 edition of The New Paper – a clear, concise daily briefing that makes fact-first news easy to consume. Try it today.